title: [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
abstract: OBJECTIVE
  To know the treatment outcome of patients with multidrug-resistant tuberculosis (MDR-TB) during gestation.
  
  
  METHODS
  Retrospective study of 3 cases of pregnant women, who were treated for MDR-TB with a regimen including pyrazinamide, ethambutol, para-aminosalicylic acid, cycloserine and amoxicillin-clavulanic acid.
  
  
  RESULTS
  All patients showed a good response to anti-tuberculosis chemotherapy without any serious adverse effect, and were culture-negative at the time of delivery. Two patients delivered vaginally at weeks 40, and one patient delivered surgically at weeks 38. All newborns were healthy, and their tuberculin skin tests and placental tissue examinations were negative for tuberculosis.
  
  
  CONCLUSIONS
  MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs.
authors.affiliation: Department of Tuberculosis Medicine, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1, Habikino, Habikino-shi, Osaka 583-8588, Japan. takashimat@opho.jp
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Takashima
authors.forename: Katsura
authors.initials: K
authors.lastname: Danno
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tamura
authors.forename: Takayuki
authors.initials: T
authors.lastname: Nagai
authors.forename: Tomoshige
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yuki
authors.initials: Y
authors.lastname: Han
authors.forename: Hiromi
authors.initials: H
authors.lastname: Ano
authors.forename: Hiroko
authors.initials: H
authors.lastname: Yoshida
authors.forename: Kunimitsu
authors.initials: K
authors.lastname: Kawahara
authors.forename: Izuo
authors.initials: I
authors.lastname: Tsuyuguchi
mesh_terms: D000328:Adult; D010131:Aminosalicylic Acid / Q000008:administration & dosage; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage; D000995:Antitubercular Agents / Q000008:administration & dosage*; D003523:Cycloserine / Q000008:administration & dosage; D018432:Drug Resistance, Multiple / Q000235:genetics; D004977:Ethambutol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000235:genetics; D036801:Parturition; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011718:Pyrazinamide / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D010131:Aminosalicylic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination; D004977:Ethambutol; D003523:Cycloserine